Novavax
NVAX
$4.15
Share price
-0.95%
Change (1 day)
-48.64%
Change (1 year)
Categories
Revenue for Novavax (NVAX)
Revenue in 2023 (TTM): $0.69 B
According to Novavax's latest financial reports the company's current revenue (TTM) is $0.69 B. In 2022 the company made a revenue of $1.39 B an increase over the years 2021 revenue that were of $1.14 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Novavax from 2001 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $0.69 B | -50.23% |
| 2022 | $1.39 B | 21.56% |
| 2021 | $1.14 B | 141.02% |
| 2020 | $0.47 B | 2448.48% |
| 2019 | $18.66 M | -45.57% |
| 2018 | $34.28 M | 9.98% |
| 2017 | $31.17 M | 103.06% |
| 2016 | $15.35 M | -57.65% |
| 2015 | $36.25 M | 18.24% |
| 2014 | $30.65 M | 46.6% |
| 2013 | $20.91 M | -5.26% |
| 2012 | $22.07 M | 50.3% |
| 2011 | $14.68 M | 4182.22% |
| 2010 | $0.34 M | 5.54% |
| 2009 | $0.32 M | -69.45% |
| 2008 | $1.06 M | -18.47% |
| 2007 | $1.3 M | -72.13% |
| 2006 | $4.68 M | -36.61% |
| 2005 | $7.38 M | -17.21% |
| 2004 | $8.92 M | -24.28% |
| 2003 | $11.78 M | -17.02% |
| 2002 | $14.2 M | -40.98% |
| 2001 | $24.06 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Novartis NVS | $51.01 B | 7,256.15% | 🇨🇭 Switzerland |
 Pfizer PFE | $58.49 B | 8,335.51% | 🇺🇸 USA |
 AstraZeneca AZN | $45.81 B | 6,506.14% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $37.84 B | 5,357.99% | 🇬🇧 UK |
 Sarepta Therapeutics
SRPT | $1.24 B | 79.29% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | $6.88 M | -99.01% | 🇺🇸 USA |
 Agenus
AGEN | $0.15 B | -77.46% | 🇺🇸 USA |
 NanoViricides NNVC | N/A | N/A | 🇺🇸 USA |
 BioCryst Pharmaceuticals
BCRX | $0.33 B | -52.21% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | $1.02 B | 47.64% | 🇺🇸 USA |